Compounds > kw 7158

Page last updated: 2024-12-11

kw 7158

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

KW 7158: an afferent nerve inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9844981
CHEMBL ID	289288
SCHEMBL ID	4688651
MeSH ID	M0440580

Synonyms (17)

Synonym
CHEMBL289288
n-(5,5-dioxo-10-oxo-4,10-dihydrothieno(3,2-c)(1)benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
kw-7158
unii-s2t07v1p1g
214764-26-8
s2t07v1p1g ,
(s)-5,5-dioxo-9-((3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino)-4,10-dihydrothieno(3,2-c)(1)benzothiepin-10-one
kw 7158
(+)-kw-7158
propanamide, n-(4,10-dihydro-5,5-dioxido-10-oxothieno(3,2-c)(1)benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2s)-
SCHEMBL4688651
DB05498
nafsypcvplwhfy-hnnxbmfysa-n
Q27095689
(s)-n-(5,5-dioxido-10-oxo-4,10-dihydrobenzo[b]thieno[2,3-e]thiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
(2s)-3,3,3-trifluoro-2-hydroxy-2-methyl-n-(5,5,10-trioxo-4h-thieno[3,2-c][1]benzothiepin-9-yl)propanamide
AKOS040748692

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" Bioavailability was relatively high with the values of 69."	( Novel LC-MS/MS method for simultaneous quantification of KW-7158, a new drug candidate for urinary incontinence and bladder hyperactivity, and its metabolites in rat plasma: a pharmacokinetic study in male and female rats. Fujita, K; Kobayashi, H; Maeda, H; Nakanishi, T; Tamai, I; Ushiki, J, 2012)	0.38

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID76396	The inhibitory concentration for 50% was measured on guinea pig bladder strips	2001	Journal of medicinal chemistry, May-24, Volume: 44, Issue:11	Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (42.86)	29.6817
2010's	4 (57.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
4-aminopyridine [no description available]	2.02	1	0	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	3.1	1	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	3.1	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
alinidine [no description available]	3.1	1	0
substance p [no description available]	2.02	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	3.1	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
bms 180448 [no description available]	3.1	1	0
u 37883a U 37883A: an antagonist of vascular ATP-sensitive potassium channel openers; structure given in first source	3.1	1	0
cromakalim Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)	3.1	1	0
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	3.1	1	0
nadp [no description available]	2.07	1	0
clamikalant clamikalant: inhibits ATP-sensitive potassium channel; structure in first source	3.1	1	0
6-cyano-4-(n-ethylsulfonyl-n-methylamino)-3-hydroxy-2,2-dimethylchromane, (trans-(+))-isomer [no description available]	3.1	1	0
bms 191095 BMS 191095: a mitochondrial K(ATP) opener; structure in first source	3.1	1	0
way 133537 [no description available]	3.1	1	0
hmr 1556 HMR 1556: an I(Ks) channel blocker; structure in first source	3.1	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Angor Pectoris [description not available]	0	2.92	1	0
Arrhythmia [description not available]	0	2.92	1	0
Asthma, Bronchial [description not available]	0	2.92	1	0
Heart Disease, Ischemic [description not available]	0	2.92	1	0
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	0	2.92	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	2.92	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	2.92	1	0
Urinary Incontinence Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.	0	3.35	2	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	2.92	1	0
Bladder, Overactive [description not available]	0	2.48	2	0
Urinary Bladder, Overactive Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.	0	2.48	2	0
Bladder Disorder, Neurogenic [description not available]	0	2.07	1	0
Urinary Bladder, Neurogenic Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.	0	2.07	1	0
Bladder Diseases [description not available]	0	2.01	1	0